NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats
Protein Science · 2023
DOI: 10.1002/pro.4593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2023. Verfasst von Britta Lipinski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab for tumor targeting. After immunization of camelids, a plethora of different VHH domains were retrieved by yeast surface display. Upon reformatting into Fc effector‐silenced NKCEs targeting NKp46 and EGFR in a strictly monovalent fashion, the resulting bispecific antibodies elicited potent NK cell‐mediated killing of EGFR‐overexpressing tumor cells with potencies (EC 50 killing) in the picomolar range. This was further augmented via co‐engagement of Fcγ receptor IIIa (FcγRIIIa). Importantly, NKp46‐specific sdAbs enabled the construction of various NKCE formats with different geometries and valencies which displayed favorable biophysical and biochemical properties without further optimization. By this means, killing capacities were further improved significantly. Hence, NKp46‐specific sdAbs are versatile building blocks for the construction of different NKCE formats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
- Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
- Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.
- Protein and Cell Sciences, Merck Healthcare KGaA, Darmstadt, Germany.
- Computational Chemistry and Biology, Merck Healthcare KGaA, Darmstadt, Germany.
ORCID-Profile: Stefan Zielonka
Zitieren
APA
Lipinski, B., Arras, P., Pekar, L., Klewinghaus, D., Boje, A. S., Krah, S., Zimmermann, J., Klausz, K., Peipp, M., Siegmund, V., Evers, A., & Zielonka, S. (2023). NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science. https://doi.org/10.1002/pro.4593
Vancouver
Lipinski B, Arras P, Pekar L, Klewinghaus D, Boje AS, Krah S, et al. NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science. 2023. doi:10.1002/pro.4593
BibTeX
@article{Lipinski2023,
author = {Lipinski, Britta and Arras, Paul and Pekar, Lukas and Klewinghaus, Daniel and Boje, Ammelie Svea and Krah, Simon and Zimmermann, Jasmin and Klausz, Katja and Peipp, Matthias and Siegmund, Vanessa and Evers, Andreas and Zielonka, Stefan},
title = {NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats},
journal = {Protein Science},
year = {2023},
doi = {10.1002/pro.4593}
}
EUVIMED